Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.17 EUR
Change Today +0.001 / 0.60%
Volume 0.0
As of 1:28 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HXB) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/1/14 - €0.36
52 Week Low
07/6/15 - €0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HXB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HXB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HXB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s primary products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts. It is also developing Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

37 Employees
Last Reported Date: 03/19/15
Founded in 1990

hemispherx biopharma inc (HXB) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.9M
Executive Vice Chairman, Chief Financial Offi...
Total Annual Compensation: $1.3M
Chief Medical Officer and Medical Director
Total Annual Compensation: $336.8K
Compensation as of Fiscal Year 2014.

hemispherx biopharma inc (HXB) Key Developments

U.S. District Court Judge Approves Hemispherx Biopharma's $2.7 Million Settlement

U.S. District Court judge approved a $2.75 million settlement that will resolve a class-action lawsuit brought by the shareholders of Hemispherx BioPharma, which alleged the company made 'material misrepresentations and omissions' regarding the status of a new drug application for its lead new drug candidate. The lawsuit - filed on behalf of investors who purchased or acquired Hemispherx stock between March 14, 2012 through December 20, 2012 - alleged Hemispherx representatives 'touted purportedly positive results from Ampligen's clinical trials'. The settlement includes a deadline of August 21, 2015 for shareholders to file claims.

Hemispherx Biopharma, Inc. Submits Application for Orphan Drug Designation to European Medicines Agency for Alferon N Injection®

Hemispherx Biopharma, Inc. announced that they have submitted an application for orphan drug designation to the European Medicines Agency (EMA) for Alferon N Injection®, an experimental therapeutic, to treat Middle East Respiratory Syndrome (MERS). The EMA has determined the application to be valid, and the Committee for Orphan Medicinal Products (COMP) has initiated the official review process. It is anticipated that the COMP will give an opinion on the application within the next 90 days. There are significant benefits for achieving Orphan Designation, including eligibility for grants from EU and Member State programs. Designated orphan medicines are assessed for marketing authorization centrally in the European Union with reductions/waivers in the fees and costs of the overall regulatory process. The designation allows companies to make a single application to the European Medicines Agency, resulting in a single opinion and a single decision from the European Commission, valid in all EU Member States. Authorized orphan medications, once commercially approved, receive benefits including ten years of complete protection from market competition with similar medicines.

Hemispherx Biopharma, Inc. Amends Restated and Amended By-Laws

On June 23, 2015, the Board of Hemispherx Biopharma, Inc. amended restated and amended By-Laws in accordance with a directive of Board of Directors to reduce the quorum, solely for the 2015 annual meeting of stockholders, from holders of a majority in voting power of the outstanding shares of stock to the holders of 40% in voting power of the outstanding shares of stock. The Board reduced the quorum, after consultation with the company's proxy advisory firm and due to low voter turnout experienced in the past.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HXB:GR €0.17 EUR +0.001

HXB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $339.50 USD +12.52
AstraZeneca PLC 4,170 GBp -20.50
Baxter International Inc $38.09 USD +0.39
Medigene AG €10.02 EUR +0.268
Sarepta Therapeutics Inc $32.03 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation HXB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 268.5x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 183.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at